SPARCC SIJ≥2* | SSS fat metaplasia ≥2 | SSS erosion ≥2 | SSS backfill ≥2 | SSS ankylosis ≥2 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Yes N=103 | No N=126 | p Value | Yes N=78 | No N=154 | p Value | Yes N=73 | No N=159 | p Value | Yes N=58 | No N=174 | p Value | Yes N=82 | No N=150 | p Value | |
All patients | |||||||||||||||
ΔmSASSS units/year (mean (SD)) | 0.74 (1.11) | 0.94 (1.50) | 0.43 | 1.09 (1.51) | 0.73 (1.23) | 0.06 | 0.56 (1.01) | 0.98 (1.44) | 0.01 | 0.89 (1.19) | 0.84 (1.38) | 0.33 | 1.12 (1.63) | 0.70 (1.12) | 0.01 |
Patients on standard therapy (N=98) | |||||||||||||||
Yes N=45 | No N=51 | p Value | Yes N=30 | No N=68 | p Value | Yes N=31 | No N=67 | p Value | Yes N=21 | No N=77 | p Value | Yes N=27 | No N=71 | p Value | |
ΔmSASSS units/year (mean (SD)) | 0.76 (1.26) | 0.77 (1.08) | 0.63 | 1.24 (1.56) | 0.57 (0.86) | 0.03 | 0.53 (0.82) | 0.89 (1.27) | 0.19 | 1.15 (1.47) | 0.67 (1.04) | 0.07 | 0.93 (1.18) | 0.72 (1.14) | 0.15 |
Patients on TNFi therapy (N=134) | |||||||||||||||
Yes N=58 | No N=75 | p Value | Yes N=48 | No N=86 | p Value | Yes N=42 | No N=92 | p Value | Yes N=37 | No N=97 | p Value | Yes N=55 | No N=79 | p Value | |
ΔmSASSS units/year (mean (SD)) | 0.73 (0.99) | 1.06 (1.73) | 0.53 | 0.99 (1.48) | 0.86 (1.45) | 0.51 | 0.59 (1.15) | 1.05 (1.56) | 0.04 | 0.75 (0.99) | 0.96 (1.60) | 0.88 | 1.22 (1.81) | 0.69 (1.11) | 0.03 |
*Available SPARCC SIJ scores n=229.
FORCAST, Follow Up Research Cohort in Ankylosing Spondylitis; SPARCC, Spondyloarthritis Research Consortium of Canada; SSS, SPARCC MRI SIJ Structural Scoring; TNFi, tumour necrosis factor inhibitor.